1、8008_Cover.indd 18008_Cover.indd 13/12/24 3:51 PM3/12/24 3:51 PMDear AbbVie Shareholder,Eleven years ago,we set out to create a company that would address some of the worlds most serious and complex health issues,while delivering outstanding shareholder return.Today,AbbVie has delivered on this miss

2、ion and much more.Our science,innovation and outstanding commercial execution have advanced the standard of care for countless patients.We have donated more than$680 million for nonprofits around the world,and we built a culture that has come to define our company.Additionally,we have provided excep

3、tional shareholder return and increased our quarterly dividend by more than 285%and market capitalization by more than$250 billion since our inception.Our business is performing very well,and we have a strong foundation for our companys growth in the years to come.In 2023,AbbVie delivered another ou

4、tstanding year of execution.We effectively managed through the biosimilar impact on Humira in the United States,and our non-Humira platform has performed well.These results are a testament to the strength of our on-market portfolio and our diverse growth platform.Total net revenues for the year of m

5、ore than$54.3 billion were primarily driven by our non-Humira growth platform that includes products across immunology,neuroscience,oncology,and aesthetics.Skyrizi and Rinvoq delivered exceptionally well with combined sales of$11.7 billion.Our neuroscience portfolio delivered sales of$7.7 billion,wh

6、ile global net revenues from our oncology portfolio were$5.9 billion and aesthetics delivered$5.3 billion.In addition to our strong financial performance,we continued to successfully manage the impact of the loss of exclusivity of Humira in the U.S.,while also investing in the future.We meaningfully